Amprenavir vs Tipranavir
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV protease · full HIV pipeline
Amprenavir
Rights held by GlaxoSmithKline; US product discontinued
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Tipranavir · Aptivus
Marketed by Boehringer Ingelheim
NCT00144170 · Phase 3 · completed
The trial randomized participants to an active comparator and included 882 enrolled participants, with 863 in the reported efficacy denominators, but the registry does not clearly report masking. Both primary virologic endpoints favored tipranavir with statistically significant comparisons; however, the primary outcomes were virologic surrogate measures rather than hard clinical outcomes, so the evidence is rated moderate.
Reported efficacy
Treatment Response at Week 48 (after 48 weeks of treatment); Time to Treatment Failure Through 48 Weeks of Treatment (after 48 weeks of treatment): Treatment Response at Week 48 (after 48 weeks of treatment): Tipranavir(TPV)/Low Dose Ritonavir(r) 34.5% vs Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r) 15% (met)
Result source: NCT00144170
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Amprenavir | Tipranavir |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Not posted · NCT00002195 | —Not reported |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not posted · NCT00002195 | —Not reported |
| CD4 count, change (week 48) | —Not posted · NCT00002195 | 41 vs 20vs Comparator Protease InhibitorNCT0014417019 other results
|
HIV-1 RNA below 50 copies/mL (week 48)
- Amprenavir
- —Not posted · NCT00002195
- Tipranavir
- —Not reported
HIV-1 RNA 50 copies/mL or more (week 48)
- Amprenavir
- —Not posted · NCT00002195
- Tipranavir
- —Not reported
CD4 count, change (week 48)
- Amprenavir
- —Not posted · NCT00002195
- Tipranavir
- 41 vs 20vs Comparator Protease InhibitorNCT00144170
19 other results
- 60 vs 28 NCT00054717
- 41 vs 19 NCT00144170
- 60 vs 29 NCT00054717
- 39 vs 19 NCT00144170
- 55 vs 26 NCT00054717
- 42 vs 18 NCT00144170
- 50 vs 24 NCT00054717
- 42 vs 13 NCT00144170
- 50 vs 26 NCT00054717
- 39 vs 16 NCT00144170
- 52 vs 26 NCT00054717
- 43 vs 16 NCT00144170
- 46 vs 28 NCT00054717
- 47 vs 19 NCT00144170
- 50 vs 24 NCT00054717
- 46 vs 17 NCT00144170
- 51 vs 26 NCT00054717
- 51 vs 21 NCT00144170
- 54 vs 24 NCT00054717
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Amprenavir: no structured comparison results are available for HIV.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Amprenavir: 0 of 4 rows · Tipranavir: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Tipranavir |
|---|---|
| Dropout rate | 80.4% NCT00144170 · Phase 3 · monotherapy · HIV · phase 3 show 1 more result83.7% NCT00054717 · Phase 3 · combination · HIV · phase 3 |
| Discontinued due to AEs | 19.2% NCT00144170 · Phase 3 · monotherapy · HIV · phase 3 show 1 more result22.4% NCT00054717 · Phase 3 · combination · HIV · phase 3 |
| Serious AEs | 28.1% NCT00144170 · Phase 3 · monotherapy · HIV · phase 3 show 1 more result36.3% NCT00054717 · Phase 3 · combination · HIV · phase 3 |
| Most frequent reported AEs | show 1 more result |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tipranavir
show 58 more results
show 3 more results
show 3 more results
show 27 more results
show 27 more results
show 1 more result
show 26 more results
show 14 more results
show 14 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Amprenavir's landscape · Tipranavir's landscape